The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Interferon signaling and treatment outcome in chronic hepatitis C
Open accessAbstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. The current standard therapy for chronic hepatitis C (CHC) consists of a combination of pegylated IFN alpha (pegIFNα) and ribavirin. It achieves a sustained viral clearance in only 50–60% of patients. To learn more about molecular mechanisms underlying treatment failure, we investigated IFN-induced signaling in paired liver biopsies collected from CHC patients before and after administration of pegIFNα. In patients with a rapid virological response to treatment, pegIFNα induced a strong up-regulation of IFN-stimulated genes (ISGs). As shown previously, nonresponders had high expression levels of ISGs before therapy. Analysis of posttreatment biopsies of these patients revealed that pegIFNα did not induce expression of ISGs above the pretreatment levels. In accordance with ISG expression data, phosphorylation, DNA binding, and nuclear localization of STAT1 indicated that the IFN signaling pathway in nonresponsive patients is preactivated and refractory to further stimulation. Some features characteristic of nonresponders were more accentuated in patients infected with HCV genotypes 1 and 4 compared with genotypes 2 and 3, providing a possible explanation for the poor response of the former group to therapy. Taken together with previous findings, our data support the concept that activation of the endogenous IFN system in CHC not only is ineffective in clearing the infection but also may impede the response to therapy, most likely by inducing a refractory state of the IFN signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., & Tschopp, J. (2005) · Nature · doi:10.1038/nature04193 · Cited by 2,401 · cited 1×
“Over the last few years, important insights into the interference of HCV with the innate immune system revealed the ability of HCV to inhibit both TLR3-TRIF-IRF3 and the RIG-I/ MDA5-Cardif signaling pathways of IFN induction (27, 28).”
BackgroundDiagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Li, K., Foy, E., Ferreon, J. C., Nakamura, M., Ferreon, A. C. M., Ikeda, M., Ray, S. C., Gale, M., & Lemon, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408824102 · Cited by 1,092
Sen, G. C. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.255 · Cited by 968
Functional classification of interferon-stimulated genes identified using microarrays
de Veer, M. J., Holko, M., Frevel, M., Walker, E., Der, S., Paranjape, J. M., Silverman, R. H., & Williams, B. R. G. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.6.912 · Cited by 900
SOCS Proteins: Negative Regulators of Cytokine Signaling
Krebs, D. L., & Hilton, D. J. (2001) · STEM CELLS · doi:10.1634/stemcells.19-5-378 · Cited by 827
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease
Thimme, R., Bukh, J., Spangenberg, H. C., Wieland, S., Pemberton, J., Steiger, C., Govindarajan, S., Purcell, R. H., & Chisari, F. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608299 · Cited by 639
Evasion of intracellular host defence by hepatitis C virus
Gale, M., & Foy, E. M. (2005) · Nature · doi:10.1038/nature04078 · Cited by 633
Gale, M., Blakely, C. M., Kwieciszewski, B., Tan, S.-L., Dossett, M., Tang, N. M., Korth, M. J., Polyak, S. J., Gretch, D. R., & Katze, M. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5208 · Cited by 605
Ferenci, P., Fried, M. W., Shiffman, M. L., Smith, C. I., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.009 · Cited by 512
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection
Bigger, C. B., Brasky, K. M., & Lanford, R. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.7059-7066.2001 · Cited by 442
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity
Malakhova, O. A., Kim, K., Luo, J., Zou, W., Kumar, K. S., Fuchs, S. Y., Shuai, K., & Zhang, D. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601149 · Cited by 431
Toll-Like Receptors and RNA Helicases: Two Parallel Ways to Trigger Antiviral Responses
Meylan, E., & Tschopp, J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.012 · Cited by 372
Expression of Hepatitis C Virus Proteins Inhibits Signal Transduction through the Jak-STAT Pathway
Heim, M. H., Moradpour, D., & Blum, H. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8469-8475.1999 · Cited by 287
Self-citationIntrahepatic Gene Expression during Chronic Hepatitis C Virus Infection in Chimpanzees
Bigger, C. B., Guerra, B., Brasky, K. M., Hubbard, G., Beard, M. R., Luxon, B. A., Lemon, S. M., & Lanford, R. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13779-13792.2004 · Cited by 259
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A
Duong, F. H. T., Filipowicz, M., Tripodi, M., La Monica, N., & Heim, M. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.076 · Cited by 222
Self-citationBlindenbacher, A., Duong, F. H. T., Hunziker, L., Stutvoet, S. T. D., Wang, X., Terracciano, L., Moradpour, D., Blum, H. E., Alonzi, T., Tripodi, M., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00290-7 · Cited by 178
Self-citationChristen, V., Treves, S., Duong, F. H. T., & Heim, M. H. (2007) · Hepatology · doi:10.1002/hep.21611 · Cited by 147
Self-citationTaylor, M. W., Tsukahara, T., Brodsky, L., Schaley, J. E., Sanda, C., Stephens, M. J., McClintick, J. N., Edenberg, H. J., Li, L., Tavis, J. E., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02640-06 · Cited by 129
Ji, X., Cheung, R. C., Cooper, S., Li, Q. S., Greenberg, H. B., & He, X.-S. (2003) · Hepatology · doi:10.1053/jhep.2003.50105 · Cited by 128
Yu, J., Wang, G., Sun, L., Li, X., & Li, S. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04904.x · Cited by 128
Lanford, R. E., Guerra, B., Lee, H., Chavez, D., Brasky, K. M., & Bigger, C. B. (2006) · Hepatology · doi:10.1002/hep.21167 · Cited by 114
Duong, F., Christen, V., Filipowicz, M., & Heim, M. (2006) · Hepatology · doi:10.1002/hep.21116 · Cited by 88
Self-citationIv, A. (2005) · 世界核心医学期刊文摘:胃肠病学分册 · Cited by 69
Lanford, R. E., Guerra, B., Bigger, C. B., Lee, H., Chavez, D., & Brasky, K. M. (2007) · Hepatology · doi:10.1002/hep.21776 · Cited by 61
Brodsky, L., Wahed, A. S., Li, J., Tavis, J. E., Tsukahara, T., & Taylor, M. W. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000584 · Cited by 25
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Metadata
- Authors
- Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-05-13
- Volume
- 105
- Issue
- 19
- Pages
- 7034-7039
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2038576929
- Cited by
- 642
- References
- 32
- FWCI
- 42.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.